Trial Profile
Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 07 Apr 2017
Price :
$35
*
At a glance
- Drugs Bupivacaine (Primary)
- Indications Peripheral vascular disorders; Raynaud's disease; Scleroderma
- Focus Pharmacodynamics
- 21 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
- 21 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
- 21 Mar 2016 Status changed from recruiting to discontinued due the the PI leaving the institution, according to ClinicalTrials.gov record.